Assumption Checking Before Application of the Prespecified QT Linear Mixed Effect Model is Essential

le Rekić, Dinko, Parkinson, Joanna, Kimko, Holly
Foilsithe in CPT Pharmacometrics Syst Pharmacol (2020)

In silico prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype

le Rekić, Dinko, Röshammar, Daniel, Mukonzo, Jackson, Ashton, Michael
Foilsithe 2011

A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated dise...

le Leander, Jacob, Sunnåker, Mikael, Rekić, Dinko, Aksenov, Sergey, Eriksson, Ulf G., Johansson, Susanne, Parkinson, Joanna
Foilsithe in J Pharmacokinet Pharmacodyn (2021)

Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy

le Rekić, Dinko, Clewe, Oskar, Röshammar, Daniel, Flamholc, Leo, Sönnerborg, Anders, Ormaasen, Vidar, Gisslén, Magnus, Äbelö, Angela, Ashton, Michael
Foilsithe 2011

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients

le Rekić, Dinko, Röshammar, Daniel, Bergstrand, Martin, Tarning, Joel, Calcagno, Andrea, D’Avolio, Antonio, Ormaasen, Vidar, Vigan, Marie, Barrail-Tran, Aurélie, Ashton, Michael, Gisslén, Magnus, Äbelö, Angela
Foilsithe 2012